Medicines Healthcare Products Regulatory Agency
Details
Information about the COVID-19 vaccine Nuvaxovid, approved by the MHRA on 3 February 2022.
The Summary of Product Characteristics is a description of a medicinal products properties and the conditions attached to its use. It explains how to use and prescribe a medicine. It is used by healthcare professionals, such as doctors, nurses and pharmacists.
The Patient Information Leaflet provides information for patients on using the medicine safely. This is based on the Summary of Product Characteristics of the product.
The original Conditional Marketing Authorisation (CMA) granted by the MHRA wais valid in Great Britain only. This was converted to a full GB Marketing Authorisation (MA) on 2 October 2023. Nuvaxovid is authorised in Northern Ireland under the CMA granted by the European Medicines Agency. on 20 December 2021. This CMA has similar requirements to that granted by the MHRA.